|
2026-06-17 |
2026-06-15 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
33 248
+25.3%
36,00
4 587 197 $US
|
33 248
+25.3%
|
36,00
|
4 587 197 $US
|
|
|
2026-06-17 |
2026-06-15 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
74 472
+49.4%
416,10
474 384 $US
|
74 472
+49.4%
|
416,10
|
474 384 $US
|
|
|
2026-06-17 |
2026-06-15 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
5 326
+0.1%
63,13
970 005 $US
|
5 326
+0.1%
|
63,13
|
970 005 $US
|
|
|
2026-06-15 |
2026-06-15 |
PrS
Vente proposée
|
Officer
Dirigeant
|
1 000
16,39
100 000 $US
|
1 000
|
16,39
|
100 000 $US
|
|
|
2026-03-18 |
2026-03-16 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
7 766
-3.2%
13,92
108 073 $US
|
7 766
-3.2%
|
13,92
|
108 073 $US
|
|
|
2026-03-18 |
2026-03-16 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
15 534
-6.1%
14,00
217 476 $US
|
15 534
-6.1%
|
14,00
|
217 476 $US
|
|
|
2026-03-18 |
2026-03-16 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
7 767
-2.9%
13,92
108 088 $US
|
7 767
-2.9%
|
13,92
|
108 088 $US
|
|
|
2026-03-16 |
2026-03-16 |
PrS
Vente proposée
|
Officer
Dirigeant
|
31 067
13,96
433 637 $US
|
31 067
|
13,96
|
433 637 $US
|
|
|
2025-12-05 |
2025-12-03 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
15 534
-5.3%
18,75
291 252 $US
|
15 534
-5.3%
|
18,75
|
291 252 $US
|
|
|
2025-12-05 |
2025-12-03 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
7 766
-2.6%
18,75
145 619 $US
|
7 766
-2.6%
|
18,75
|
145 619 $US
|
|
|
2025-12-05 |
2025-12-03 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
7 767
-2.5%
18,75
145 630 $US
|
7 767
-2.5%
|
18,75
|
145 630 $US
|
|
|
2025-12-03 |
2025-12-03 |
PrS
Vente proposée
|
Officer
Dirigeant
|
31 067
18,75
582 500 $US
|
31 067
|
18,75
|
582 500 $US
|
|
|
2025-12-01 |
2025-11-26 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
15 501
-25.7%
20,00
310 020 $US
|
15 501
-25.7%
|
20,00
|
310 020 $US
|
|
|
2025-12-01 |
2025-11-26 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
14 000
-18.9%
20,00
280 000 $US
|
14 000
-18.9%
|
20,00
|
280 000 $US
|
|
|
2025-11-26 |
2025-11-26 |
PrS
Vente proposée
|
Director
Administrateur non-exécutif
|
29 501
20,00
590 020 $US
|
29 501
|
20,00
|
590 020 $US
|
|
|
2025-11-13 |
2025-11-11 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
14 000
-23.3%
18,50
259 000 $US
|
14 000
-23.3%
|
18,50
|
259 000 $US
|
|
|
2025-11-13 |
2025-11-11 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
15 500
-25.1%
17,00
263 500 $US
|
15 500
-25.1%
|
17,00
|
263 500 $US
|
|
|
2025-11-13 |
2025-11-11 |
PlS
Vente planifiée
|
Administrateur non-exécutif
|
29 500
-32.3%
18,50
545 750 $US
|
29 500
-32.3%
|
18,50
|
545 750 $US
|
|
|
2025-11-12 |
2025-11-11 |
PrS
Vente proposée
|
Director
Administrateur non-exécutif
|
45 000
17,98
809 250 $US
|
45 000
|
17,98
|
809 250 $US
|
|
|
2025-07-16 |
2025-07-14 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.2%
11,39
45 552 $US
|
4 000
-1.2%
|
11,39
|
45 552 $US
|
|
|
2025-07-16 |
2025-07-14 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
5 318
-1.6%
11,39
60 548 $US
|
5 318
-1.6%
|
11,39
|
60 548 $US
|
|
|
2025-07-16 |
2025-07-14 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
682
-0.2%
11,39
7 770 $US
|
682
-0.2%
|
11,39
|
7 770 $US
|
|
|
2025-07-14 |
2025-07-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
10 000
11,39
113 869 $US
|
10 000
|
11,39
|
113 869 $US
|
|
|
2025-06-04 |
2025-06-02 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
24 000
-6.6%
11,00
264 000 $US
|
24 000
-6.6%
|
11,00
|
264 000 $US
|
|
|
2025-06-02 |
2025-06-02 |
PrS
Vente proposée
|
Officer
Dirigeant
|
24 000
11,00
264 000 $US
|
24 000
|
11,00
|
264 000 $US
|
|
|
2025-04-23 |
2025-04-21 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.1%
9,00
36 000 $US
|
4 000
-1.1%
|
9,00
|
36 000 $US
|
|
|
2025-01-23 |
2025-01-21 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.3%
9,00
36 000 $US
|
4 000
-1.3%
|
9,00
|
36 000 $US
|
|
|
2025-01-21 |
2025-01-21 |
PrS
Vente proposée
|
Officer
Dirigeant
|
4 000
9,00
36 000 $US
|
4 000
|
9,00
|
36 000 $US
|
|
|
2024-11-13 |
2024-11-11 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.2%
9,00
36 000 $US
|
4 000
-1.2%
|
9,00
|
36 000 $US
|
|
|
2024-08-09 |
2024-08-07 |
A
Achat
|
Actionnaire important
|
999 800
+11.7%
7,80
7 798 440 $US
|
999 800
+11.7%
|
7,80
|
7 798 440 $US
|
|
|
2024-07-12 |
2024-07-10 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.2%
9,00
36 000 $US
|
4 000
-1.2%
|
9,00
|
36 000 $US
|
|
|
2024-05-03 |
2024-05-01 |
A
Achat
|
Actionnaire important
|
499 324
+6.2%
8,75
4 369 085 $US
|
499 324
+6.2%
|
8,75
|
4 369 085 $US
|
|
|
2024-05-03 |
2024-05-01 |
A
Achat
|
Actionnaire important
|
999 800
+14.3%
8,75
8 748 250 $US
|
999 800
+14.3%
|
8,75
|
8 748 250 $US
|
|
|
2024-02-22 |
2024-02-22 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
1 254
-0.4%
8,71
10 922 $US
|
1 254
-0.4%
|
8,71
|
10 922 $US
|
|
|
2023-11-22 |
2023-11-21 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
1 378
-0.4%
10,29
14 180 $US
|
1 378
-0.4%
|
10,29
|
14 180 $US
|
|
|
2023-11-16 |
2023-11-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 482
-0.7%
10,22
25 366 $US
|
2 482
-0.7%
|
10,22
|
25 366 $US
|
|
|
2023-11-14 |
2023-11-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 482
10,22
25 366 $US
|
2 482
|
10,22
|
25 366 $US
|
|
|
2023-10-18 |
2023-10-16 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 482
-0.7%
9,03
22 412 $US
|
2 482
-0.7%
|
9,03
|
22 412 $US
|
|
|
2023-10-16 |
2023-10-16 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 482
9,03
22 412 $US
|
2 482
|
9,03
|
22 412 $US
|
|
|
2023-09-18 |
2023-09-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 482
-0.7%
9,89
24 547 $US
|
2 482
-0.7%
|
9,89
|
24 547 $US
|
|
|
2023-09-14 |
2023-09-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 482
9,89
24 547 $US
|
2 482
|
9,89
|
24 547 $US
|
|
|
2023-08-24 |
2023-08-22 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
1 807
-0.5%
9,47
17 112 $US
|
1 807
-0.5%
|
9,47
|
17 112 $US
|
|
|
2023-08-15 |
2023-08-11 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 322
-0.7%
9,99
23 197 $US
|
2 322
-0.7%
|
9,99
|
23 197 $US
|
|
|
2023-08-11 |
2023-08-11 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 322
9,99
23 197 $US
|
2 322
|
9,99
|
23 197 $US
|
|
|
2023-07-18 |
2023-07-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 322
-0.7%
9,84
22 848 $US
|
2 322
-0.7%
|
9,84
|
22 848 $US
|
|
|
2023-07-14 |
2023-07-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 322
9,84
22 848 $US
|
2 322
|
9,84
|
22 848 $US
|
|
|
2023-06-16 |
2023-06-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 322
-0.7%
10,69
24 822 $US
|
2 322
-0.7%
|
10,69
|
24 822 $US
|
|
|
2023-06-14 |
2023-06-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 322
10,69
24 822 $US
|
2 322
|
10,69
|
24 822 $US
|
|
|
2023-06-12 |
2023-06-08 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
1 790
-0.5%
11,13
19 923 $US
|
1 790
-0.5%
|
11,13
|
19 923 $US
|
|
|
2023-06-08 |
2023-06-08 |
PrS
Vente proposée
|
Officer
Dirigeant
|
1 790
11,13
19 923 $US
|
1 790
|
11,13
|
19 923 $US
|
|
|
2023-05-17 |
2023-05-15 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 322
-0.6%
11,26
26 146 $US
|
2 322
-0.6%
|
11,26
|
26 146 $US
|
|
|
2023-05-15 |
2023-05-15 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 322
11,26
26 146 $US
|
2 322
|
11,26
|
26 146 $US
|
|
|
2023-04-18 |
2023-04-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 323
-0.6%
11,88
27 597 $US
|
2 323
-0.6%
|
11,88
|
27 597 $US
|
|
|
2023-04-14 |
2023-04-14 |
PrS
Vente proposée
|
Officer
Dirigeant
|
2 323
11,88
27 597 $US
|
2 323
|
11,88
|
27 597 $US
|
|
|
2023-03-16 |
2023-03-14 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 323
-0.6%
10,32
23 973 $US
|
2 323
-0.6%
|
10,32
|
23 973 $US
|
|
|
2023-03-13 |
2023-03-09 |
V
Vente
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
4 000
-1.1%
10,20
40 800 $US
|
4 000
-1.1%
|
10,20
|
40 800 $US
|
|
|
2023-03-08 |
2023-03-06 |
PlS
Vente planifiée
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 323
-0.6%
10,05
23 346 $US
|
2 323
-0.6%
|
10,05
|
23 346 $US
|
|
|
2022-12-16 |
2022-12-14 |
V
Vente
|
CHIEF EXECUTIVE OFFICER
Administrateur exécutif
|
50 000
-3.6%
11,19
559 500 $US
|
50 000
-3.6%
|
11,19
|
559 500 $US
|
|
|
2022-12-05 |
2022-12-01 |
V
Vente
|
SVP, RESEARCH & DEVELOPMENT
Dirigeant
|
2 084
-0.7%
10,73
22 361 $US
|
2 084
-0.7%
|
10,73
|
22 361 $US
|
|
|
2022-11-22 |
2022-11-18 |
V
Vente
|
SVP, CHIEF FINANCIAL OFFICER
Dirigeant
|
65 000
-13.7%
11,02
716 242 $US
|
65 000
-13.7%
|
11,02
|
716 242 $US
|
|
|
2022-08-18 |
2022-08-16 |
V
Vente
|
SVP, DEVELOPMENT
Dirigeant
|
4 906
-1.3%
9,71
47 640 $US
|
4 906
-1.3%
|
9,71
|
47 640 $US
|
|
|
2022-08-11 |
2022-08-09 |
V
Vente
|
SVP, DEVELOPMENT
Dirigeant
|
15 086
-3.9%
8,79
132 606 $US
|
15 086
-3.9%
|
8,79
|
132 606 $US
|
|
|
2022-05-24 |
2022-05-23 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
1 081
-0.3%
8,93
9 653 $US
|
1 081
-0.3%
|
8,93
|
9 653 $US
|
|
|
2022-03-02 |
2022-02-28 |
PlS
Vente planifiée
|
SVP, COMM & MEDICAL AFFAIRS
Dirigeant
|
2 356
-0.7%
10,16
23 947 $US
|
2 356
-0.7%
|
10,16
|
23 947 $US
|
|
|
2021-03-11 |
2021-03-09 |
V
Vente
|
SVP, Research & Transl Science
Dirigeant
|
8 829
-2.5%
20,00
176 580 $US
|
8 829
-2.5%
|
20,00
|
176 580 $US
|
|
|
2020-12-16 |
2020-12-14 |
V
Vente
|
SVP, Development
Dirigeant
|
7 500
-5.7%
19,47
146 058 $US
|
7 500
-5.7%
|
19,47
|
146 058 $US
|
|
|
2020-12-07 |
2020-12-03 |
V
Vente
|
SVP, Research & Transl Science
Dirigeant
|
4 246
-1.3%
18,00
76 428 $US
|
4 246
-1.3%
|
18,00
|
76 428 $US
|
|
|
2020-08-24 |
2020-08-21 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
25 000
-8.1%
18,29
457 240 $US
|
25 000
-8.1%
|
18,29
|
457 240 $US
|
|
|
2020-08-24 |
2020-08-20 |
V
Vente
|
SVP, Research & Transl Science
Dirigeant
|
17 103
-4.9%
18,00
307 854 $US
|
17 103
-4.9%
|
18,00
|
307 854 $US
|
|
|
2019-12-16 |
2019-12-12 |
V
Vente
|
SABESAN VIJAY
SVP, Technical Operations
Dirigeant
|
1 027
-0.7%
21,03
21 598 $US
|
1 027
-0.7%
|
21,03
|
21 598 $US
|
|
|
2019-05-20 |
2019-05-17 |
V
Vente
|
|
2 673
-8.8%
20,19
53 968 $US
|
2 673
-8.8%
|
20,19
|
53 968 $US
|
|
|
2019-05-20 |
2019-05-16 |
V
Vente
|
|
1 327
-4.2%
21,00
27 867 $US
|
1 327
-4.2%
|
21,00
|
27 867 $US
|
|
|
2019-03-06 |
2019-03-05 |
V
Vente
|
SVP, Research
|
5 690
-2.1%
24,50
139 405 $US
|
5 690
-2.1%
|
24,50
|
139 405 $US
|
|
|
2019-03-06 |
2019-03-04 |
V
Vente
|
SVP, Research
|
3 343
-1.2%
25,06
83 764 $US
|
3 343
-1.2%
|
25,06
|
83 764 $US
|
|
|
2018-09-14 |
2018-09-12 |
V
Vente
|
WORBOYS PHILIP D
SVP, Translational Science
Dirigeant
|
6 393
-3.7%
28,50
182 200 $US
|
6 393
-3.7%
|
28,50
|
182 200 $US
|
|